Advertisement

The importance of non-pharmacological treatment in spondyloarthritis

Published:September 07, 2021DOI:https://doi.org/10.1016/j.ejim.2021.08.025
      Spondyloarthritis (SpA) is a related group of inflammatory joint diseases comprising axial SpA (axSpA), psoriatic arthritis (PsA), arthritis associated with inflammatory bowel disease, reactive arthritis and undifferentiated SpA [
      • Sieper J.
      • Braun J.
      • Dougados M.
      • et al.
      Axial spondyloarthritis.
      ]. These entities share clinical features like asymmetrical oligoarticular arthritis, sacroiliitis and/or spondylitis, enthesitis, dactylitis and/or uveitis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sieper J.
        • Braun J.
        • Dougados M.
        • et al.
        Axial spondyloarthritis.
        Nat Rev Dis Primers. 2015; 1 (https://doi.org/)https://doi.org/10.1038/nrdp.2015.13
        • Rudwaleit M
        • van der Heijde D
        • Landewe R
        • et al.
        The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection.
        Ann Rheum Dis. 2009; 68 (https://doi.org/): 777-783https://doi.org/10.1136/ard.2009.108233
        • Rudwaleit M
        • Van der Heijde D
        • Landewe R
        • et al.
        The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.
        Ann Rheum Dis. 2011; 70 (https://doi.org/): 25-31https://doi.org/10.1136/ard.2010.133645
        • Van der Heijde D.
        • et al.
        2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
        Ann Rheum Dis. 2017; 76 (http://doi:): 978-991https://doi.org/10.1136/annrheumdis-2016-210770
        • Smolen J.S.
        • Schols M.
        • et al.
        Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
        Ann Rheum Dis. 2018; 77 (http://doi): 3-17https://doi.org/10.1136/annrheumdis-2017-211734
        • Lange U
        • Müller-Ladner U
        • Dischereit G.
        Rheumatic diseases and molecular physical medicine - new aspects.
        Phys Medizin, Rehabil Kurortmedizin. 2017; 27 (https://doi.org/): 205-210https://doi.org/10.1055/s-0043-113045
        • Lakomek HJ
        • Fiori W
        • Buscham K
        • et al.
        Complex and multimodal rheumatologic treatment (OPS 8-983) - challenges, solutions and perspectives.
        Z Rheumatol. 2005; 64: 557-563
        • Klemm P
        • Preusler P
        • et al.
        Multimodal rheumatologic complex treatment in patients with spondyloarthritis - prospective study.
        Eur J Internal Med. 2021; (https://doi.org/)https://doi.org/10.1016/j.ejim.2021.07.005
        • Klemm P
        • Eichelmann M
        • Aykara I
        • et al.
        Serial locally applied water- filtered infrared a radiation in axial spondyloarthritis- a randomized controlled trial.
        Int J Hyperth. 2020; 37 (https://doi.org/): 965-970https://doi.org/10.1080/02656736.2020.1804079